CAMP4 Therapeutics is a clinical-stage biopharmaceutical enterprise dedicated to developing a novel pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression and restore healthy protein levels in patients with severe genetic disorders. Utilizing its proprietary RAP Platform, the company maps regulatory RNAs that act locally on transcription factors, creating targeted antisense oligonucleotide drug candidates intended to address haploinsufficient and recessive partial loss-of-function diseases that currently lack effective medical interventions.